INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2024

Investments, All Other Investments [Abstract]

Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis

The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):

	September 30, 2024
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash and cash equivalents, excluding money market accounts	$	110,296	$	—	$	—	$	110,296	$	110,296	$	—
Level 1:
Money market accounts	5,011		—		—		5,011		5,011		—
Government & agency securities	16,600		118		114		16,832		—		16,832
Equity securities	10,000		(3,584)		—		6,416		—		6,416
	31,611		(3,466)		114		28,259		5,011		23,248
Level 2:
Corporate bonds	30,742		344		314		31,400		—		31,400
Total	$	172,649	$	(3,122)	$	428	$	169,955	$	115,307	$	54,648

	December 31, 2023
	Cost		Unrealized Gains		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash and cash equivalents, excluding money market accounts	$	88,778	$	—	$	—	$	88,778	$	88,778	$	—
Level 1:
Money market accounts	5,662		—		—		5,662		5,662		—
Government & agency securities	15,282		126		40		15,448		—		15,448
Equity securities	10,000		150		—		10,150		—		10,150
	30,944		276		40		31,260		5,662		25,598
Level 2:
Corporate bonds	29,440		293		270		30,003		—		30,003
Total	$	149,162	$	569	$	310	$	150,041	$	94,440	$	55,601

Schedule of Investment Losses

The losses related to the Company’s LifeMD investment for the three and nine months ended September 30, 2024 and 2023 are summarized in the table below (in thousands):

	Three months ended September 30,
	2024		2023
Net losses recognized during the period on equity securities	$	(1,984)	$	—
Less: Net losses recognized on equity securities sold	—		—
Unrealized losses recognized during the reporting period on equity securities still held at the reporting date	$	(1,984)	$	—

	Nine months ended September 30,
	2024		2023
Net losses recognized during the period on equity securities	$	(3,734)	$	—
Less: Net losses recognized on equity securities sold	—		—
Unrealized losses recognized during the reporting period on equity securities still held at the reporting date	$	(3,734)	$	—